About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered ...

, /PRNewswire/ - BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that none of its fixed rate Cumulative Redeemable First Preferred Shares, Series R (Series R Preferred Shares) will be converted into floating rate Cumulative Redeemable First Preferred Shares, Series Q (Series Q Preferred Shares) on December 1, 2025.  Based on total revenue and total combined customer connections. Media inquiries Ellen Murphy [email protected] Investor inquiries Krishna Somers [email protected] On October 17, 2025, BCE no ...

New design enhances water loop cleanliness and enables removal of in-row CDUs in high density applications, optimizing PUE and freeing space for additional IT racks. , /PRNewswire/ -- Modine (NYSE: MOD), a diversified global leader in thermal management technology and solutions, today announced the addition of a stainless steel variant to its flagship Airedale by Modineâ"¢ TurboChillâ"¢Â DCS chiller range. The stainless steel design provides the hydraulic capacity needed for direct liquid cooling (DLC) syst ...

Management to Hold Conference Call at 8:30 a.m. EST Learn more about who we are, what we do, and how we do it atwww.biolinerx.com, or onLinkedIn. CONTACTS: United States Irina Koffler LifeSci Advisors, LLC [email protected] Israel Moran Meir LifeSci Advisors, LLC [email protected] Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg , /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and ...

Pre-Tax NPV5% of US$3.2 billion, Pre-Tax IRR of 54% After-Tax NPV5% of US$2.1 billion, After-Tax IRR of 41% Average Annual Gold Production of 330 koz and AISC of US$877/oz in Years 1 through 5 , /PRNewswire/ - First Mining Gold Corp. ("First Mining" or the "Company") (TSX: FF) (OTCQX: FFMGF) (FRANKFURT: FMG) is pleased to announce the positive results of an updated Pre-Feasibility Study ("2025PFS") completed for its 100%-owned Springpole Gold Project (the "Project" or "Springpole") located in Ontario, C ...

, /PRNewswire/ -- RADCOM Ltd. (Nasdaq: RDCM)Â announced today that it has secured a contract for its Smart Network Visibility Solution through Rakuten Symphony for a leading mobile operator. Acting as a critical layer between the network and a mobile operator's service assurance platform, the solution delivers accurate, intelligent data collection with flexible options for retention and delivery. This enables a comprehensive end-to-end view of the network while significantly reducing monitoring costs. About ...

Core Points - Quanta Services, Inc. has declared a quarterly cash dividend of $0.11 per share, which annualizes to $0.44 per share [1] - This represents an approximate 10.0% increase from the previous quarterly cash dividend paid in October 2025 [1] - The dividend is scheduled to be payable on January 12, 2026, to stockholders of record as of January 2, 2026 [1]

Core Insights - The article discusses a new strategic agreement between Vertiv and Caterpillar aimed at enhancing data center efficiency and resilience through integrated energy solutions [1] Company Collaboration - Vertiv, a leader in critical digital infrastructure, and Caterpillar, a leader in power systems, will collaborate on advanced energy optimization solutions specifically for data centers [1] Industry Impact - The partnership is expected to improve deployment timelines and overall operational efficiency within the data center industry, addressing the growing demand for reliable energy solutions [1]

Core Insights - The company reported a 2.3% increase in net sales for the full fiscal year, driven by acquisition net sales of $63.6 million and organic net sales growth of 0.7% [1] - Reported EPS was $3.32, while adjusted EPS increased by 6% to $3.52 [1] - Net earnings reached $239.0 million, with adjusted EBITDA at $623.6 million [1] - The Project Momentum initiative achieved over $200 million in savings during its three-year program and will be extended into a fourth year [1] - The focus of the extended Project Momentum will be on ongoing tariff mitigation, increasing operational efficiency, and integrating the APS business [1] Fourth Quarter Results - For the fourth quarter, net sales increased by 3.4% to $832.8 million, driven by acquisition net sales of $42.8 million, although organic net sales declined by 2.2% [1] - Reported EPS for the fourth quarter was $0.50, with adjusted EPS at $1.05 [1]

Core Insights - Medtronic plc reported a strong Q2 FY26 with revenue of $9.0 billion, reflecting a 6.6% increase as reported and 5.5% organic growth, exceeding guidance midpoint by 75 basis points [1] - The company raised its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66 [1] - Cardiac Ablation Solutions experienced significant growth of 71%, with a remarkable 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio [1] Financial Performance - GAAP diluted EPS increased by 8% to $1.07, while non-GAAP diluted EPS also rose by 8% to $1.36, both above guidance [1] - The cardiovascular segment achieved its strongest revenue growth in over a decade, excluding pandemic effects [1] Product Developments - The company received broad favorable National Coverage Determination (NCD) from U.S. Centers for Medicare & Medicaid Services (CMS) for the Symplicity™ procedure, targeting an addressable market of 18 million people with uncontrolled hypertension [1] - Medtronic secured U.S. FDA approval for the Altaviva™ device, aimed at treating urge urinary incontinence, which affects over 16 million people in the U.S. [1] - The Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints in the Enable Hernia Repair study and initiated the Embrace Gynecology US pivotal study [1] - The U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes [1]